Perizat Mukhamedzhanova
Research Subjects
Research Interests
Perizat Mukhamedzhanova has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Abay Baigenzhin
National Scientific Medical Center, Astana 010009, Kazakhstan
2 shared publications - Aigul Brimova
International Oncological Tomotherapy Center “YMIT”, 42/1 Abilay Khan Ave., Astana 010009, Kazakhstan
2 shared publications - Anastasia Ganina
National Scientific Medical Center, Astana 010009, Kazakhstan
2 shared publications - Daulet Berikbol
International Oncological Tomotherapy Center “YMIT”, 42/1 Abylay Khan ave., Astana 010000, Kazakhstan
2 shared publications - Elmira Chuvakova
Deputy Chairman of the Board in the field of science, National Scientific Medical Center, Astana, Kazakhstan
2 shared publications - Larissa Kozina
JSC National Scientific Medical Center, 42 Abylay Khan ave., Astana 010009, Kazakhstan
2 shared publications
Latest Publications
- Open Access
- 6 December 2024
- Published by MDPI AG in Advances in Respiratory Medicine
- Vol. 92 (6) , 504-525
Prospects for Treatment of Lung Cancer Using Activated Lymphocytes Combined with Other Anti-Cancer Modalities
This review explores the significance and prospects of using diverse T-cell variants in the context of combined therapy for lung cancer treatment. Recently, there has been an increase in research focused on understanding the critical role of tumor-specific T lymphocytes and the potential benefits of autologous T-cell-based treatments for individuals with lung cancer. One promising approach involves intravenous administration of ex vivo-activated autologous lymphocytes to improve the immune status of patients with cancer. Investigations are also exploring the factors that influence the success of T-cell therapy and the methods used to stimulate them. Achieving a comprehensive understanding of the characteristics of activated lymphocytes and deciphering the mechanisms underlying their activation of innate anti-tumor immunity will pave the way for numerous clinical trials and the development of innovative strategies for cancer therapy like combined immunotherapy and radiation therapy.
- 6 December 2024
- Published by MDPI AG in Advances in Respiratory Medicine
- Vol. 92 (6) , 504-525
Open AccessProspects for Treatment of Lung Cancer Using Activated Lymphocytes Combined with Other Anti-Cancer Modalities
This review explores the significance and prospects of using diverse T-cell variants in the context of combined therapy for lung cancer treatment. Recently, there has been an increase in research focused on understanding the critical role of tumor-specific T lymphocytes and the potential benefits of autologous T-cell-based treatments for individuals with lung cancer. One promising approach involves intravenous administration of ex vivo-activated autologous lymphocytes to improve the immune status of patients with cancer. Investigations are also exploring the factors that influence the success of T-cell therapy and the methods used to stimulate them. Achieving a comprehensive understanding of the characteristics of activated lymphocytes and deciphering the mechanisms underlying their activation of innate anti-tumor immunity will pave the way for numerous clinical trials and the development of innovative strategies for cancer therapy like combined immunotherapy and radiation therapy.
- Open Access
- 31 October 2024
- Published by MDPI AG in Preprints.org
Prospects for Combined Treatment of Non-Small Cell Lung Cancer Using Autologous Activated Lymphocytes
This review article explores the significance and prospects of using diverse T-cell variants in the context of combined therapy for lung cancer treatment. Recently, there has been an increase in research focused on understanding the critical role of tumor-specific T-lymphocytes and the potential benefits of autologous T-cell-based treatments for individuals with lung cancer. One promising approach involves intravenous administration of ex vivo-activated autologous lymphocytes to improve the immune status of patients with cancer. Investigations are also exploring the factors that influence the success of T-cell therapy and the methods used to stimulate them. Achieving a comprehensive understanding of the characteristics of activated lymphocytes and deciphering the mechanisms underlying their activation of innate anti-tumor immunity will pave the way for numerous clinical trials and the development of innovative strategies for cancer therapy.
- 31 October 2024
- Published by MDPI AG in Preprints.org
Open AccessProspects for Combined Treatment of Non-Small Cell Lung Cancer Using Autologous Activated Lymphocytes
This review article explores the significance and prospects of using diverse T-cell variants in the context of combined therapy for lung cancer treatment. Recently, there has been an increase in research focused on understanding the critical role of tumor-specific T-lymphocytes and the potential benefits of autologous T-cell-based treatments for individuals with lung cancer. One promising approach involves intravenous administration of ex vivo-activated autologous lymphocytes to improve the immune status of patients with cancer. Investigations are also exploring the factors that influence the success of T-cell therapy and the methods used to stimulate them. Achieving a comprehensive understanding of the characteristics of activated lymphocytes and deciphering the mechanisms underlying their activation of innate anti-tumor immunity will pave the way for numerous clinical trials and the development of innovative strategies for cancer therapy.